An aging geriatrician wonders: Who will care for me?

Fewer doctors are choosing geriatrics as a specialty, yet the number of Americans 65 and older keeps growing. An aging geriatrician sees problems ahead.

By Jerry H. Gurwitz

STAT+ | To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare's worst option

First Opinion: For CMS to cover all who are overweight or obese, Novo's purchase price would be recouped in 22 months through GLP-1 purchases alone.

By Melissa Barber, Joseph S. Ross, and Reshma Ramachandran

Sonya Massey's death: How to prevent more killings of defenseless Black women

Crisis Intervention Trainings should be mandatory for all police officers, and mental health crisis teams should be funded and deployed for de-escalation.

By Onyeka T. Otugo and Adaira I. Landry

Rich Pedroncelli/AP

The newest tool to prevent STIs is not available to everyone: A call for participatory and inclusive research

Taking the antibiotic doxycycline after sex proved effective in controlling STIs in certain populations. Expert urges expanding doxy PEP use to all.

By Oni Blackstock and Whitney C. Irie

Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it

There's an overlooked innovation in the FDA's non-approval of MDMA for PTSD — combining a medication and a psychotherapy as a bundled intervention.

By Thomas R. Insel

NIDA should beware of funding companies that violate people's privacy

NIDA and other funders should ensure that online addiction treatment companies aren't violating users' privacy by illegally sharing data.

By Jonathan JK Stoltman and Mishka Terplan

Adobe

Fixing the reimbursement and coverage divide between 'breakthrough' drugs and medical devices

First Opinion: After FDA approval, Medicare treats breakthrough medical devices differently than it treats breakthrough drugs. It's time for a change.

By Richard Macary

STAT+ | Cell donors are essential for new therapies. They need to be taken care of

First Opinion essay discusses how to recruit, retain, and compensate cell and tissue donors, and how to ensure their safety throughout the donation process.

By Priya Baraniak

STAT+ | Medtech compliance — not regulation — is stifling innovation

To transform compliance from a red tape burden to a real guardrail, medtech companies should adopt developer-first approaches like shift-left testing.